293 related articles for article (PubMed ID: 32437738)
1. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
[TBL] [Abstract][Full Text] [Related]
2. Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.
Gotlib J; Kluin-Nelemans HC; Akin C; Hartmann K; Valent P; Reiter A
Expert Opin Biol Ther; 2021 Apr; 21(4):487-498. PubMed ID: 33063554
[TBL] [Abstract][Full Text] [Related]
3. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W; Gotlib J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
[TBL] [Abstract][Full Text] [Related]
4. Response and progression on midostaurin in advanced systemic mastocytosis:
Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
Gotlib J; Kluin-Nelemans HC; George TI; Akin C; Sotlar K; Hermine O; Awan FT; Hexner E; Mauro MJ; Sternberg DW; Villeneuve M; Huntsman Labed A; Stanek EJ; Hartmann K; Horny HP; Valent P; Reiter A
N Engl J Med; 2016 Jun; 374(26):2530-41. PubMed ID: 27355533
[TBL] [Abstract][Full Text] [Related]
6. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
[TBL] [Abstract][Full Text] [Related]
7. Midostaurin: a magic bullet that blocks mast cell expansion and activation.
Valent P; Akin C; Hartmann K; George TI; Sotlar K; Peter B; Gleixner KV; Blatt K; Sperr WR; Manley PW; Hermine O; Kluin-Nelemans HC; Arock M; Horny HP; Reiter A; Gotlib J
Ann Oncol; 2017 Oct; 28(10):2367-2376. PubMed ID: 28945834
[TBL] [Abstract][Full Text] [Related]
8. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird JH; Gotlib J
Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
[TBL] [Abstract][Full Text] [Related]
10. Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.
Lübke J; Schwaab J; Naumann N; Horny HP; Weiß C; Metzgeroth G; Kreil S; Cross NCP; Sotlar K; Fabarius A; Hofmann WK; Valent P; Gotlib J; Jawhar M; Reiter A
J Clin Oncol; 2022 Jun; 40(16):1783-1794. PubMed ID: 35235417
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo DJ; George TI; Linder A; Langford C; Perkins C; Ma J; Westervelt P; Merker JD; Berube C; Coutre S; Liedtke M; Medeiros B; Sternberg D; Dutreix C; Ruffie PA; Corless C; Graubert TJ; Gotlib J
Leukemia; 2018 Feb; 32(2):470-478. PubMed ID: 28744009
[TBL] [Abstract][Full Text] [Related]
12. Novel approaches to treating advanced systemic mastocytosis.
Gilreath JA; Tchertanov L; Deininger MW
Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
[TBL] [Abstract][Full Text] [Related]
13. The new tool "
Shomali W; Gotlib J
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):127-136. PubMed ID: 30504301
[TBL] [Abstract][Full Text] [Related]
14. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
[TBL] [Abstract][Full Text] [Related]
15. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells.
Krauth MT; Mirkina I; Herrmann H; Baumgartner C; Kneidinger M; Valent P
Clin Exp Allergy; 2009 Nov; 39(11):1711-20. PubMed ID: 19860818
[TBL] [Abstract][Full Text] [Related]
16. Kit Mutations: New Insights and Diagnostic Value.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.
Gotlib J; Baird JH; George TI; Langford C; Reyes I; Abuel J; Perkins C; Schroeder K; Bose P; Verstovsek S
Blood Adv; 2019 Aug; 3(15):2264-2271. PubMed ID: 31350306
[TBL] [Abstract][Full Text] [Related]
18. Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.
Pilkington H; Smith S; Roskell N; Iannazzo S
Future Oncol; 2022 Apr; 18(13):1583-1594. PubMed ID: 35114819
[TBL] [Abstract][Full Text] [Related]
19. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
